There is a Mary Ann Liebert at Mary Ann Liebert, Inc.

And that makes a difference!

For Immediate Release

Microbiota-Gut-Brain Axis is at Epicenter of New Approach to Mental Health, as Described in OMICS Microbiome Special Issue

Contact: Kathryn Ryan
914-740-2250
kryan@liebertpub.com

Mary Ann Liebert, Inc.
140 Huguenot Street
New Rochelle, NY 10801
(914) 740-2100 or (800) M-LIEBERT
Fax (914) 740-2101
www.liebertpub.com

New Rochelle, NY, February 26, 2018—The functional gut microbiome provides an exciting new therapeutic target for treating psychiatric disorders such as anxiety and trauma-related conditions. Innovative methods for studying and intervening in gut microbiome composition and activity to treat mental illness and maintain mental health are presented in a timely review article that is part of the “Microbiome Special Issue: Food, Drugs, Diagnostics, and Built Environments” of OMICS: A Journal of Integrative Biology, the peer-reviewed interdisciplinary journal published by Mary Ann Liebert, Inc., publishers. The special issue is available free on the OMICS website until March 26, 2018.
 
In the article “The Gut Microbiome and Mental Health: Implications for Anxiety- and Trauma-Related Disorders,” Stefanie Malan-Muller, Stellenbosch University (Stellenbosch, South Africa) and coauthors review the emerging findings of microbiome research in psychiatric disorders. They encourage the mental health community to embrace microbiome science as a new frontier of biological psychiatry and postgenomic medicine.
 
Culturomics: A New Kid on the Block of OMICS to Enable Personalized Medicine,” an article coauthored by Manousos Kambouris, The Golden Helix Foundation (London, U.K.) and University of Patras (Patras, Greece) and colleagues, examine the new field of culturomics and how it may widen the scope of microbiology and expand its contributions to diagnostics and personalized medicine. The researchers also explore potential applications in agriculture, environmental sciences, pharmacomicrobiomics, and biotechnology innovation and the value of the Big Data produced by culturomics.
 
Kieran O’Doherty, University of Guelph, Canada, and coauthors discuss the opportunity and challenges for integrating human microbiome research into clinical practice to improve the diagnosis and treatment of patients with inflammatory bowel disease. The authors describe how patient-specific microbiome data could help guide therapeutic decision-making in the article entitled “Human Microbiome and Learning Healthcare Systems: Integrating Research and Precision Medicine for Inflammatory Bowel Disease.”
 
Vural Özdemir, MD, PhD, DABCP, Editor-in-Chief of OMICS, has commented that “microbiome projects are booming and unraveling the microbial dark matter from humans and animals to built habitats on our planet. Microbiome research will continue to bring about insights into human health, disease susceptibility, and mechanisms of person-to-person variations in response to food, drugs, vaccines, and other health interventions, thus supporting precision medicine and the discovery of innovative diagnostics.”
 
OMICS: A Journal of Integrative Biology is an authoritative and highly innovative peer-reviewed interdisciplinary journal published monthly online, addressing the latest advances at the intersection of postgenomics medicine, biotechnology and global society, including the integration of multi-omics knowledge, data analyses and modeling, and applications of high-throughput approaches to study complex biological and societal problems. Public policy, governance and societal aspects of the large-scale biology and 21st century data-enabled sciences are also peer-reviewed. Complete tables of content and a sample issue may be viewed on the OMICS: A Journal of Integrative Biology website.
 
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research, including Journal of Computational Biology, ASSAY and Drug Development Technologies, and Zebrafish. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert 2, Inc.
140 Huguenot Street
New Rochelle, NY 10801
(914) 740-2100 or (800) M-LIEBERT
Fax (914) 740-2101
www.liebertpub.com